Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C MunshiLarry D AndersonNina ShahDeepu MadduriJesús BerdejaSagar LonialNoopur RajeYi LinDavid S SiegelAlbert OriolPhilippe MoreauIbrahim Yakoub AghaMichel DelforgeMichele CavoHermann EinseleHartmut GoldschmidtKatja WeiselAlessandro RambaldiDonna ReeceFabio PetroccaMonica MassaroJamie N ConnarnShari KaiserPayal PatelLiping HuangTimothy B CampbellKristen HegeJesús San-MiguelPublished in: The New England journal of medicine (2021)
Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).